AMR Vocabulary
| Term | Definition |
|---|---|
| ST | Sequence type |
| STAAR | Strategies to Address Antimicrobial Resistance, US act introduced November 2007 |
| TB | Tuberculosis |
| TEAE | Treatment emergent adverse events |
| TOC | Test-of-cure |
| Triple I | (Impact Investment Initiative for Global Health): An initiative endorsed at the 2023 G7 Hiroshima Summit focused on connecting stakeholders and mobilizing private capital through impact investment. It aims to address critical global health issues—including the financial and developmental burdens of antimicrobial resistance (AMR)—by driving sustainable private and public financing, particularly in low- and middle-income countries (LMICs). |
| TRL | Technology Readiness Level, term and system developed to guide on a product or service’s go-to-market maturity |
| TTO | Technology Transfer Office, entity at university dedicated to bringing academic inventions to use by industry and society |
| TTP | Time to positivity |
| UDI | Unique Device Identifier |
| UDR | (Usual Drug Resistance): Any resistance profile that is not MDR, XDR, or PDR. This is the current expected pattern of susceptibility to available agents. There will be non-susceptibility to some agents but first-line therapies are reliably active. |
| UNITAID | A global health initiative that works to improve access to and affordability of drugs, diagnostics, and other health tools for HIV/AIDS, malaria, and tuberculosis in low- and middle-income countries. It operates by shaping markets and investing in innovations. |
| UTI | Urinary tract infection |
| uUTI | Uncomplicated urinary tract infection |
| VABP | Ventilator-associated bacterial pneumonia |
| VAP | Ventilator-associated pneumonia |
| VetReg | Veterinary Prescription Register |
| vHABP | Ventilated hospital-acquired bacterial pneumonia |
| VMP | Veterinary medicinal product |
| VRE | Vancomycin-resistant enterococci |
| WBA | Whole blood activity |
| WBC | White blood cell |
| WGS | Whole genome sequence |
| WHO | World Health Organization |
| WT | Wild type |
| XDR | (eXtensive Drug Resistance): non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e., bacterial isolates remain susceptible to only one or two categories). |